Base de dados : MEDLINE
Pesquisa : C08.127.446.135.140 [Categoria DeCS]
Referências encontradas : 2516 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 252 ir para página                         

  1 / 2516 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457921
[Au] Autor:Budding K; Rossato M; van de Graaf EA; Kwakkel-van Erp JM; Radstake TRDJ; Otten HG
[Ad] Endereço:Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: k.budding@umcutrecht.nl.
[Ti] Título:Serum miRNAs as potential biomarkers for the bronchiolitis obliterans syndrome after lung transplantation.
[So] Source:Transpl Immunol;42:1-4, 2017 06.
[Is] ISSN:1878-5492
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Lung transplantation (LTx) is the last treatment for patients suffering from end-stage lung diseases. Survival post-LTx is hampered by the development of the bronchiolitis obliterans syndrome (BOS) and diagnosis is often late. Given the urgent clinical need to recognize BOS patients at an early stage, we analyzed circulating miRNAs to identify possible stratification markers for BOS development post-transplantation. Therefore, pro-fibrotic (miR-21, miR-155), anti-fibrotic (miR-29a) and fibrosis-unrelated (miR-103, miR-191) miRNAs were analyzed in serum of end-stage lung disease patients and during LTx follow-up. Significant elevated levels of serum miRNAs were observed for all investigated miRNAs in both chronic obstructive pulmonary disease and interstitial lung disease patients compared to healthy controls. The same miRNAs were also significantly increased in the serum of BOS+ vs. BOS- patients. Most importantly, miR-21, miR-29a, miR-103, and miR-191 levels were significantly higher in BOS+ patients prior to clinical BOS diagnosis. We demonstrated that a selected group of miRNAs investigated is elevated in end-stage lung disease and BOS+ patients, prior to clinical BOS diagnosis. Even if further research is expedient on the prognostic value of circulating miRNAs in BOS and lung conditions in general, these results strongly suggest that circulating miRNAs could be used as potential biomarkers for BOS development.
[Mh] Termos MeSH primário: Bronquiolite Obliterante/sangue
Transplante de Pulmão
MicroRNAs/sangue
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Doença Pulmonar Obstrutiva Crônica/sangue
Estudos Retrospectivos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (MicroRNAs)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  2 / 2516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29178919
[Au] Autor:Fakhro M; Broberg E; Algotsson L; Hansson L; Koul B; Gustafsson R; Wierup P; Ingemansson R; Lindstedt S
[Ad] Endereço:Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden. mohammed.fakhro@med.lu.se.
[Ti] Título:Double lung, unlike single lung transplantation might provide a protective effect on mortality and bronchiolitis obliterans syndrome.
[So] Source:J Cardiothorac Surg;12(1):100, 2017 Nov 25.
[Is] ISSN:1749-8090
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Survival after lung transplantation (LTx) is often limited by bronchiolitis obliterans syndrome (BOS). METHOD: Survey of 278 recipients who underwent LTx. The endpoint used was BOS (BOS grade ≥ 2), death or Re-lung transplantation (Re-LTx) assessed by competing risk regression analyses. RESULTS: The incidence of BOS grade ≥ 2 among double LTx (DLTx) recipients was 16 ± 3% at 5 years, 30 ± 4% at 10 years, and 37 ± 5% at 20 years, compared to single LTx (SLTx) recipients whose corresponding incidence of BOS grade ≥ 2 was 11 ± 3%, 20 ± 4%, and 24 ± 5% at 5, 10, and 20 years, respectively (p > 0. 05). The incidence of BOS grade ≥ 2 by major indications ranked in descending order: other, PF, CF, COPD, PH and AAT1 (p < 0. 05). The mortality rate by major indication ranked in descending order: COPD, PH, AAT1, PF, Other and CF (p < 0. 05). CONCLUSION: No differences were seen in the incidence of BOS grade ≥ 2 regarding type of transplant, however, DLTx recipients showed a better chance of survival despite developing BOS compared to SLTx recipients. The highest incidence of BOS was seen among CF, PF, COPD, PH, and AAT1 recipients in descending order, however, CF and PF recipients showed a better chance of survival despite developing BOS compared to COPD, PH, and AAT1 recipients.
[Mh] Termos MeSH primário: Bronquiolite Obliterante/etiologia
Transplante de Pulmão/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Bronquiolite Obliterante/epidemiologia
Bronquiolite Obliterante/prevenção & controle
Criança
Feminino
Seres Humanos
Incidência
Transplante de Pulmão/métodos
Masculino
Meia-Idade
Taxa de Sobrevida/tendências
Suécia/epidemiologia
Síndrome
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1186/s13019-017-0666-5


  3 / 2516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457374
[Au] Autor:Pecoraro Y; Carillo C; Diso D; Mantovani S; Cimino G; De Giacomo T; Troiani P; Shafii M; Gherzi L; Amore D; Rendina EA; Venuta F; Anile M
[Ad] Endereço:Department of Thoracic Surgery, Policlinico Umberto I, Sapienza University of Rome, Italy. Electronic address: ylenia.pecoraro@uniroma1.it.
[Ti] Título:Efficacy of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation.
[So] Source:Transplant Proc;49(4):695-698, 2017 May.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lung transplantation (LT) is only therapeutic option for patients affected by chronic respiratory failure. Chronic rejection, also known as bronchiolitis obliterans syndrome (BOS), is still the main cause of death and the most important factor that influences post-transplantation quality of life. Currently available therapies have not been proven to result in significant benefit in the prevention or treatment of BOS. Extracorporeal photopheresis (ECP) seems to reduce the rate of lung function decline in transplant recipients with progressive BOS. METHODS: From 1991 until now, 239 LTs were performed at our center. Fifty-four patients (22.5%) developed BOS; 15 of these (27.7%) were treated with ECP. At the beginning of the treatment, all patients showed a mean decline of forced expiratory volume in 1 second (FEV ) from baseline values of 45.8% ± 17.2%; 2 patients were in long-term oxygen therapy. RESULTS: Mean follow-up from November 2013 to June 2016 was 11.6 ± 7 months. Twelve patients (80%) showed lung function stabilization with an FEV range after treatment between -6% to +8% from the pre-treatment values. We did not report any adverse effects or increase of infections incidence. DISCUSSION: ECP seems to be an effective and well-tolerated therapeutic option for LT patients with BOS in terms of stabilization of lung function and increased survival.
[Mh] Termos MeSH primário: Bronquiolite Obliterante/etiologia
Bronquiolite Obliterante/terapia
Rejeição de Enxerto/terapia
Transplante de Pulmão/efeitos adversos
Fotoferese/métodos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171212
[Lr] Data última revisão:
171212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  4 / 2516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28926522
[Au] Autor:Hodge G; Hodge S; Yeo A; Nguyen P; Hopkins E; Holmes-Liew CL; Reynolds PN; Holmes M
[Ad] Endereço:1 Lung Research, Hanson Institute and Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia. 2 Department of Medicine, University of Adelaide, Adelaide, South Australia. 3 South Australian Lung Transplant Service, Adelaide, South Australia.
[Ti] Título:BOS Is Associated With Increased Cytotoxic Proinflammatory CD8 T, NKT-Like, and NK Cells in the Small Airways.
[So] Source:Transplantation;101(10):2469-2476, 2017 Oct.
[Is] ISSN:1534-6080
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Immunosuppression therapy after lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients, primarily a disease of the small airways. We have reported that BOS is associated with a lack of suppression of cytotoxic mediators, and proinflammatory cytokines, in peripheral blood T, NKT-like (particularly CD8+) and NK cells. We also showed a loss of glucocorticoid receptor (GCR) in proinflammatory lymphocytes after transplant. It is unknown whether these proinflammatory lymphocytes target the small and/or large airways in BOS. METHODS: Blood, bronchoalveolar lavage, large proximal, and small distal airway brushings were collected from patients with BOS (n = 10), stable lung transplant patients (n = 18), and healthy aged-matched controls (n = 10). Intracellular cytotoxic mediators (perforin/granzyme B), proinflammatory cytokines (IFNγ/TNFα), and expression of GCR were determined in lymphocytes subsets from cultured blood using flow cytometry. RESULTS: Increases in CD8 T cells, NKT-like cells, and NK cells were found in the small distal airways in BOS compared with stable patients and controls. An increase in perforin, granzyme B, IFNγ, TNFα, and a loss of GCR from these lymphocyte subsets was also found in BOS. GCR expression by CD8+ T cells from small airways correlated with FEV1 (R = 0.834, P = 0.039). Many of these changes significantly differed from those in the large airways. CONCLUSIONS: BOS is associated with increased cytotoxic/proinflammatory CD8+ T, NKT-like, and NK cells in the small airways. Treatments that increase GCR in these lymphocyte subsets may improve graft survival.
[Mh] Termos MeSH primário: Brônquios/patologia
Bronquiolite Obliterante/imunologia
Linfócitos T CD8-Positivos/patologia
Imunidade Celular
Células Matadoras Naturais/patologia
Transplante de Pulmão/efeitos adversos
Perforina/biossíntese
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biópsia
Brônquios/imunologia
Brônquios/metabolismo
Bronquiolite Obliterante/metabolismo
Bronquiolite Obliterante/patologia
Líquido da Lavagem Broncoalveolar/química
Linfócitos T CD8-Positivos/imunologia
Feminino
Seres Humanos
Células Matadoras Naturais/imunologia
Contagem de Linfócitos
Masculino
Meia-Idade
Período Pós-Operatório
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
126465-35-8 (Perforin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE
[do] DOI:10.1097/TP.0000000000001592


  5 / 2516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28787506
[Au] Autor:Bergeron A; Chevret S; Granata A; Chevallier P; Vincent L; Huynh A; Tabrizi R; Labussiere-Wallet H; Bernard M; Chantepie S; Bay JO; Thiebaut-Bertrand A; Thepot S; Contentin N; Fornecker LM; Maillard N; Risso K; Berceanu A; Blaise D; Peffault de La Tour R; Chien JW; Coiteux V; Socié G; ALLOZITHRO Study Investigators
[Ad] Endereço:AP-HP, Hôpital Saint-Louis, Service de Pneumologie, Paris, France.
[Ti] Título:Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.
[So] Source:JAMA;318(6):557-566, 2017 08 08.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome. Objective: To evaluate if the early administration of azithromycin can improve airflow decline-free survival after allogeneic HSCT. Design, Setting, and Participants: The ALLOZITHRO parallel-group trial conducted in 19 French academic transplant centers and involving participants who were at least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had available pretransplant pulmonary function test results. Enrollment was from February 2014 to August 2015 with follow-up through April 26, 2017. Interventions: Patients were randomly assigned to receive 3 times a week either 250 mg of azithromycin (n = 243) or placebo (n = 237) for 2 years, starting at the time of the conditioning regimen. Main Outcomes and Measures: The primary efficacy end point was airflow decline-free survival at 2 years after randomization. Main secondary end points were overall survival and bronchiolitis obliterans syndrome at 2 years. Results: Thirteen months after enrollment, the independent data and safety monitoring board detected an unanticipated imbalance across blinded groups in the number of hematological relapses, and the treatment was stopped December 26, 2016. Among 480 randomized participants, 465 (97%) were included in the modified intention-to-treat analysis (mean age, 52 [SD, 14] years; 75 women [35%]). At the time of data cutoff, 104 patients (22%; 54 azithromycin vs 50 placebo) had experienced an airflow decline; 138 patients (30%) died (78 azithromycin vs 60 placebo). Two-year airflow decline-free survival was 32.8% (95% CI, 25.9%-41.7%) with azithromycin and 41.3% (95% CI, 34.1%-50.1%) with placebo (unadjusted hazard ratio [HR], 1.3; 95% CI, 1.02-1.70; P = .03). Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the azithromycin group and 7 (3%) in the placebo group (P = .08). The azithromycin group had increased mortality, with a 2-year survival of 56.6% (95% CI, 50.2%-63.7%) vs 70.1% (95% CI, 64.2%-76.5%) in the placebo group (unadjusted HR, 1.5; 95% CI, 1.1-2.0; P = .02). In a post hoc analysis, the 2-year cumulative incidence of hematological relapse was 33.5% (95% CI, 27.3%-39.7%) with azithromycin vs 22.3% (95% CI, 16.4%-28.2%) with placebo (unadjusted cause-specific HR, 1.7; 95% CI, 1.2-2.4; P = .002). Conclusions and Relevance: Among patients undergoing allogeneic HSCT for hematological malignancy, early administration of azithromycin resulted in worse airflow decline-free survival than did placebo; these findings are limited by early trial termination. The potential for harm related to relapse requires further investigation. Trial Registration: clinicaltrials.gov Identifier: NCT01959100.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Azitromicina/uso terapêutico
Bronquiolite Obliterante/prevenção & controle
Neoplasias Hematológicas/terapia
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
[Mh] Termos MeSH secundário: Adulto
Antibacterianos/efeitos adversos
Azitromicina/efeitos adversos
Bronquiolite Obliterante/etiologia
Intervalo Livre de Doença
Método Duplo-Cego
Feminino
Neoplasias Hematológicas/mortalidade
Seres Humanos
Análise de Intenção de Tratamento
Masculino
Meia-Idade
Recidiva
Testes de Função Respiratória
Condicionamento Pré-Transplante
Transplante Homólogo
Falha de Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 83905-01-5 (Azithromycin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170809
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.9938


  6 / 2516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28734446
[Au] Autor:Tanaka S; Miyoshi K; Sugimoto S; Yamane M; Kobayashi M; Oto T
[Ad] Endereço:Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.
[Ti] Título:Successful Lung Transplantation Using a Deceased Donor Mechanically Ventilated for Ten Months.
[So] Source:Ann Thorac Surg;104(2):e177-e179, 2017 Aug.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:A successful outcome after lung transplant was achieved using lungs donated from a teenage boy who underwent prolonged mechanical ventilation. The donor experienced hypoxic brain damage and was declared brain dead 324 days after tracheal intubation. At the time of referral, the donor's lungs revealed diffuse radiologic infiltration and atelectasis but excellent function, with a PaO /FiO ratio of 450. The lungs were transplanted to a 10-year-old girl with bronchiolitis obliterans. She developed grade 2 primary graft dysfunction, but recovered quickly. She is doing well and has not experienced any other critical adverse events 12 months after lung transplantation.
[Mh] Termos MeSH primário: Bronquiolite Obliterante/cirurgia
Transplante de Pulmão/métodos
Respiração Artificial/métodos
Doadores de Tecidos
Obtenção de Tecidos e Órgãos/métodos
[Mh] Termos MeSH secundário: Criança
Feminino
Seguimentos
Seres Humanos
Masculino
Fatores de Tempo
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170724
[St] Status:MEDLINE


  7 / 2516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28574386
[Au] Autor:Mustafayev I; Allahverdyeva L; Bogdanova A
[Ad] Endereço:1Research Institute of Lung Diseases, Baku; 2State Medical University, Baku, Azerbaijan; 3Research Institute of Pulmonology of The Pavlov First Saint Petersburg State Medical University, Sankt-Petersburg, Russia.
[Ti] Título:[IMMUNE RESPONSE IN CHRONIC BRONCHIOLITIS OBLITERANS IN CHILDREN].
[So] Source:Georgian Med News;(265):66-70, 2017 Apr.
[Is] ISSN:1512-0112
[Cp] País de publicação:Georgia (Republic)
[La] Idioma:rus
[Ab] Resumo:The qaim of the research was to evaluate a condition of cellular and humoral immunity in 139 children with bronchiolitis obliterans in age from 2 years to 14 years of life. There was a minor immunosuppression during exacerbation followed by normalization in remission. There was a slight decrease in the level of IgA, an increased concentration of IgM and high value of the circulating immune complexes during the exacerbation with normalization as acute inflammation subsided. An analysis of interleukin dynamics revealed a significant increase in the concentration of pro- and anti-inflammatory cytokines in the acute stage of the disease with a tendency to normalization in remission. Thus, there is no place marked immunosuppression. Analyzed changes are adequate and are a response to viral and bacterial infection.
[Mh] Termos MeSH primário: Bronquiolite Obliterante/imunologia
[Mh] Termos MeSH secundário: Adolescente
Criança
Pré-Escolar
Doença Crônica
Feminino
Seres Humanos
Imunidade Celular
Imunidade Humoral
Imunoglobulina A/sangue
Imunoglobulina G/sangue
Imunoglobulina M/sangue
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (Immunoglobulin M)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170603
[St] Status:MEDLINE


  8 / 2516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28545478
[Au] Autor:Tu ZL; Zhou ZY; Xu HC; Cao JL; Ye P; Wang LM; Lv W; Hu J
[Ad] Endereço:Department of Thoracic Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University, NO. 79 Qingchun Road, Hangzhou, 310003, China.
[Ti] Título:LTB4 and montelukast in transplantation-related bronchiolitis obliterans in rats.
[So] Source:J Cardiothorac Surg;12(1):43, 2017 May 25.
[Is] ISSN:1749-8090
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lung transplantation is the only effective treatment for end-stage lung diseases. Bronchiolitis obliterans, which is known as non-infectious chronic lung allograft dysfunction (CLAD) in the new classification, is the greatest threat to long-term survival after lung transplantation. This study investigated the role of leukotriene B4 (LTB4) and montelukast in transplantation-related bronchiolitis obliterans and discussed the pathophysiological significance of LTB4 in chronic rejection. METHODS: Rats were randomly divided into an experimental group (montelukast), a positive control group (dexamethasone), and a blank control group (normal saline solution; NS). Each piece of trachea removed from a F344 rat was transplanted into a Lewis rat through a 5-mm incision at the episternum by subcutaneous embedding. The recipients were treated with gastric lavage with 3 mg/kg · d montelukast suspension, 1 mg/kg · d dexamethasone, and 1 mL/kg · d NS, respectively, in each group. On Day 28, peripheral blood was drawn to measure the white blood cell counts and plasma LTB4 levels. The donor specimens were stained by H-E and Masson, and their organizational structure and extent of fibrosis were visually assessed. The measurement data were compared using one-way analysis of variance, and the categorical data were compared using the chi-square test. A P value of less than 0.05 was considered to indicate statistical significance. RESULTS: The white blood cell counts of the montelukast, dexamethasone, and NS groups were (16.0 ± 4.2) × 10 /L, (19.5 ± 11.6) × 10 /L, and (25.8 ± 3.6) × 10 /L; no statistical significance was found (P = 0.101). The concentrations of LTB4 were 2230 ± 592 pg/mL, 1961 ± 922 pg/mL, and 3764 ± 1169 pg/mL, and statistical significance was found between the NS group and each of the others (P = 0.009). The percentages of tracheal occlusion were 73.6% ± 13.8%, 23.4% ± 3.2%, and 89.9% ± 11.3%, and statistical significance was found among the three groups (P = 0.000). CONCLUSIONS: The study established a model to simulate bronchiolitis obliterans after clinical lung transplantation. Oral administration of montelukast reduced plasma LTB4 levels in rats and played a preventive role against tracheal fibrosis after transplantation. This suggests that LTB4 may be involved in bronchiolitis obliterans after pulmonary transplantation. This study indicates a new direction for research into the prevention and treatment of bronchiolitis obliterans after lung transplantation.
[Mh] Termos MeSH primário: Acetatos/administração & dosagem
Bronquiolite Obliterante/etiologia
Rejeição de Enxerto/etiologia
Leucotrieno B4/sangue
Transplante de Pulmão/efeitos adversos
Quinolinas/administração & dosagem
[Mh] Termos MeSH secundário: Administração Oral
Animais
Bronquiolite Obliterante/sangue
Bronquiolite Obliterante/tratamento farmacológico
Modelos Animais de Doenças
Rejeição de Enxerto/sangue
Rejeição de Enxerto/tratamento farmacológico
Antagonistas de Leucotrienos/administração & dosagem
Masculino
Ratos
Ratos Endogâmicos F344
Ratos Endogâmicos Lew
Transplante Homólogo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetates); 0 (Leukotriene Antagonists); 0 (Quinolines); 1HGW4DR56D (Leukotriene B4); MHM278SD3E (montelukast)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170527
[St] Status:MEDLINE
[do] DOI:10.1186/s13019-017-0605-5


  9 / 2516 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28427861
[Au] Autor:Schütte-Nütgen K; Boenisch O; Harrach H; Casey A; Guleria I; Najafian N; Sayegh MH; Gerard CJ; Subramaniam M
[Ad] Endereço:Pulmonary Division, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Internal Medicine D, University Hospital Münster, Münster, Germany.
[Ti] Título:Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans.
[So] Source:Am J Pathol;187(6):1368-1379, 2017 Jun.
[Is] ISSN:1525-2191
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Costimulatory molecules, such as the programmed death ligand (PD-L1), might exert differential effects on T-cell function, depending on the clinical setting and/or immunological environment. Given the impact of T cells on bronchiolitis obliterans (BO) in lung transplantation, we used an established tracheal transplant model inducing BO-like lesions to investigate the impact of PD-L1 on alloimmune responses and histopathological outcome in BO. In contrast to other transplant models in which PD-L1 generally shows protective functions, we demonstrated that PD-L1 has divergent effects depending on its location in donor versus recipient tissue. Although PD-L1 deficiency in donor tissue worsened histopathological outcome, and increased systemic inflammatory response, recipient PD-L1 deficiency induced opposite effects. Mechanistic studies revealed PD-L1-deficient recipients were hyporesponsive toward alloantigen, despite increased numbers of CD8 effector T cells. The function of PD-L1 on T cells after unspecific stimulation was dependent on both cell type and strength of stimulation. This novel function of recipient PD-L1 may result from the high degree of T-cell activation within the highly immunogenic milieu of the transplanted tissue. In this model, both decreased T-cell alloimmune responses and the reduction of BO in PD-L1-deficient recipients suggest a potential therapeutic role of selectively blocking PD-L1 in the recipient. Further investigation is warranted to determine the impact of this finding embedded in the complex pathophysiological context of BO.
[Mh] Termos MeSH primário: Antígeno B7-H1/imunologia
Bronquiolite Obliterante/imunologia
Traqueia/transplante
Imunologia de Transplantes
[Mh] Termos MeSH secundário: Animais
Antígeno B7-H1/deficiência
Bronquiolite Obliterante/patologia
Bronquiolite Obliterante/prevenção & controle
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD8-Positivos/imunologia
Modelos Animais de Doenças
Células Epiteliais/imunologia
Sobrevivência de Enxerto/imunologia
Tolerância Imunológica/imunologia
Imunidade Celular
Isoantígenos/imunologia
Ativação Linfocitária/imunologia
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos C57BL
Doadores de Tecidos
Traqueia/patologia
Regulação para Cima/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (B7-H1 Antigen); 0 (Cd274 protein, mouse); 0 (Isoantigens)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE


  10 / 2516 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28415888
[Au] Autor:Cova E; Inghilleri S; Pandolfi L; Morosini M; Magni S; Colombo M; Piloni D; Finetti C; Ceccarelli G; Benedetti L; Cusella MG; Agozzino M; Corsi F; Allevi R; Mrakic-Sposta S; Moretti S; De Gregori S; Prosperi D; Meloni F
[Ad] Endereço:a Clinica di Malattie dell'Apparato Respiratorio , IRCCS Fondazione Policlinico San Matteo , Pavia , Italy.
[Ti] Título:Bioengineered gold nanoparticles targeted to mesenchymal cells from patients with bronchiolitis obliterans syndrome does not rise the inflammatory response and can be safely inhaled by rodents.
[So] Source:Nanotoxicology;11(4):534-545, 2017 May.
[Is] ISSN:1743-5404
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The use of gold nanoparticles (GNPs) as drug delivery system represents a promising issue for diseases without effective pharmacological treatment due to insufficient local drug accumulation and excessive systemic toxicity. Bronchiolitis obliterans syndrome (BOS) represents about 70% of cases of chronic lung allograft dysfunction, the main challenge to long-term lung transplantation. It is believed that due to repeated insults to epithelial bronchiolar cells local inflammatory response creates a milieu that favors epithelial-mesenchymal transition and activation of local mesenchymal cells (MCs) leading to airway fibro-obliteration. In a previous work, we engineered GNPs loaded with the mammalian target of rapamycin inhibitor everolimus, specifically decorated with an antibody against CD44, a surface receptor expressed by primary MCs isolated from bronchoalveolar lavage of BOS patients. We proved in vitro that these GNPs (GNP-HCe) were able to specifically inhibit primary MCs without affecting the bronchial epithelial cell. In the present work, we investigated the effect of these bioengineered nanoconstructs on inflammatory cells, given that a stimulating effect on macrophages, neutrophils or lymphocytes is strongly unwanted in graft airways since it would foster fibrogenesis. In addition, we administered GNP-HCe by the inhalatory route to normal mice for a preliminary assessment of their pulmonary and peripheral (liver, spleen and kidney) uptake. By these experiments, an evaluation of tissue toxicity was also performed. The present study proves that our bioengineered nanotools do not rise an inflammatory response and, under the tested inhalatory conditions that were used, are non-toxic.
[Mh] Termos MeSH primário: Bronquiolite Obliterante/imunologia
Células Epiteliais/efeitos dos fármacos
Ouro/farmacologia
Células Mesenquimais Estromais/efeitos dos fármacos
Nanopartículas Metálicas
[Mh] Termos MeSH secundário: Animais
Bronquiolite Obliterante/complicações
Líquido da Lavagem Broncoalveolar/citologia
Líquido da Lavagem Broncoalveolar/imunologia
Proliferação Celular/efeitos dos fármacos
Células Epiteliais/imunologia
Transição Epitelial-Mesenquimal/efeitos dos fármacos
Transição Epitelial-Mesenquimal/imunologia
Everolimo/administração & dosagem
Ouro/administração & dosagem
Ouro/química
Seres Humanos
Receptores de Hialuronatos/imunologia
Imunossupressores/administração & dosagem
Exposição por Inalação
Pulmão/efeitos dos fármacos
Pulmão/imunologia
Transplante de Pulmão/efeitos adversos
Masculino
Células Mesenquimais Estromais/imunologia
Nanopartículas Metálicas/administração & dosagem
Nanopartículas Metálicas/química
Camundongos Endogâmicos C57BL
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CD44 protein, human); 0 (Hyaluronan Receptors); 0 (Immunosuppressive Agents); 7440-57-5 (Gold); 9HW64Q8G6G (Everolimus)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE
[do] DOI:10.1080/17435390.2017.1317862



página 1 de 252 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde